West Pharmaceutical's Q3 Adjusted Earnings, Sales Rise; 2026 Outlook Increased

06:47 AM EDT, 10/29/2026 (MT Newswires) -- West Pharmaceutical Services (WST) reported Q3 adjusted earnings Thursday of $2.66 per diluted share, up from $1.96 a year earlier. Analysts surveyed by FactSet expected $2.20. Net sales for the quarter ended Sept. 30 were $874.5 million, up from $804.6 million a year earlier. Analysts expected $827.1 million. For 2026, the company said it now expects adjusted EPS to be between $9.38 and $9.48, up from the previous outlook of between $8.85 and $9.05. Analysts expect $8.98. Net sales for the year are now projected to be between $3.41 billion and $3.42 billion, up from the prior outlook of between $3.345 billion and $3.380 billion. Analysts are looking for $3.38 billion.